The Pulse Check

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Dec 19, 2025

•

11 min read

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Jason Segal

The Pulse Check

Putting ASX Healthcare in the Hot Seat in 2026

Dec 18, 2025

•

6 min read

Putting ASX Healthcare in the Hot Seat in 2026

Jason Segal

The Pulse Check

Same Result. Two Markets. Very Different Answers.

Dec 17, 2025

•

9 min read

Same Result. Two Markets. Very Different Answers.

Jason Segal

The Pulse Check

The Holiday Trade I like to do once a Year

Dec 16, 2025

•

7 min read

The Holiday Trade I like to do once a Year

Jason Segal

The Pulse Check

Trump floats new cannabis rules: Weeding out the good from the bad

Dec 15, 2025

•

11 min read

Trump floats new cannabis rules: Weeding out the good from the bad

Jason Segal

The Pulse Check

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Dec 12, 2025

•

9 min read

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Jason Segal

The Pulse Check

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Dec 11, 2025

•

9 min read

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Jason Segal

Imugene (ASX: IMU)

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Dec 10, 2025

•

9 min read

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Jason Segal

The Pulse Check

Immutep drops a US$370M deal... at 6:54pm

Dec 9, 2025

•

7 min read

Immutep drops a US$370M deal... at 6:54pm

Jason Segal

The Pulse Check

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Dec 8, 2025

•

11 min read

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Jason Segal

The Pulse Check

Are AI-Predicted Clinical Trials the Future of Drug Development?

Dec 5, 2025

•

5 min read

Are AI-Predicted Clinical Trials the Future of Drug Development?

Jason Segal

The Pulse Check

The Moment Invion (IVX) Became “Investible” for me

Dec 4, 2025

•

7 min read

The Moment Invion (IVX) Became “Investible” for me

Jason Segal

The Pulse Check

Dec 3, 2025

•

7 min read

The Hidden Signals Found in AGM Updates

Jason Segal

Visionflex Group (ASX:VFX)

Dec 2, 2025

•

6 min read

Inside the Visionflex Lazarus Story

Jason Segal

The Pulse Check

What happens when a biotech stock goes up on "no news"...

Dec 1, 2025

•

5 min read

What happens when a biotech stock goes up on "no news"...

Jason Segal

The Pulse Check

Biotech green shoots emerge in Australia and the US

Nov 28, 2025

•

4 min read

Biotech green shoots emerge in Australia and the US

Jason Segal

The Pulse Check

What does a "leveraged" clinical trial bet look like

Nov 27, 2025

•

5 min read

What does a "leveraged" clinical trial bet look like

Jason Segal

The Pulse Check

Paul Hopper voted out, PIQ gets Reimbursement, Ethics Approval for RAC

Nov 26, 2025

•

6 min read

Paul Hopper voted out, PIQ gets Reimbursement, Ethics Approval for RAC

Jason Segal

The Pulse Check

Philips swings big at ASX listed minnows

Nov 25, 2025

•

4 min read

Philips swings big at ASX listed minnows

Jason Segal

The Pulse Check

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Putting ASX Healthcare in the Hot Seat in 2026

Same Result. Two Markets. Very Different Answers.

The Holiday Trade I like to do once a Year

Trump floats new cannabis rules: Weeding out the good from the bad

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Immutep drops a US$370M deal... at 6:54pm

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Are AI-Predicted Clinical Trials the Future of Drug Development?

The Moment Invion (IVX) Became “Investible” for me

The Hidden Signals Found in AGM Updates

Inside the Visionflex Lazarus Story

What happens when a biotech stock goes up on "no news"...

Biotech green shoots emerge in Australia and the US

What does a "leveraged" clinical trial bet look like

Paul Hopper voted out, PIQ gets Reimbursement, Ethics Approval for RAC

Philips swings big at ASX listed minnows

The Armchair Analyst